The global hepatitis B treatment market is anticipated to expand at a robust CAGR during the forecast period, between 2021 and 2028. Hepatitis is mainly caused by liver infection, which can be caused by excessive consumption of alcohol and drugs, or due to certain medical problems. The disease is contagious and some of the common sources for transmission of the disease are due to coming into contact with consuming contaminated water, infected blood, and using infected syringes or needles. Sexual transmission of Hepatitis B can be happened due to frequent intercourse with sex workers, unprotected sex practices, and sex with several partners. Hepatitis B patients are likely to experience a variety of symptoms including weakness, loss of appetite, dark-colored urine, jaundice, swelling in the legs, itching on the skin, drowsiness, weight loss, and others.
Market Trends, Drivers, Restraints, and Opportunities:
- Favorable government support for raising hepatitis awareness as well as the growing availability of technologically improved for therapy medicines are projected to propel market expansion during the forecast period.
- Rising global prevalence of Hepatitis B, increasing number of the elderly population, and rising incidence of viral infection are key factors driving market growth.
- Increasing prevalence of sexually transmitted illnesses and rising healthcare spending are expected to boost the market expansion in the coming years.
- Negative effects from treatment and drugs applications are major challenges that can hinder the market growth.
- The COVID-19 pandemic and high medicine prices are acting as key restraining factors hampering the overall market revenue.
- Introduction of new treatment devices and massive R&D programs for the development of innovative treatment methods are projected to provide significant growth opportunities for the market.
Scope of the report:
The report on the global hepatitis B treatment market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Hepatitis B Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2020
|
|
Historic Data
|
2018 & 2019
|
|
Forecast Period
|
2021–2028
|
|
Segmentation
|
Types (Chronic and Acute), Treatments (Antiviral Drugs [Entecavir, Lamivudine, Telbivudine, Tenofovir Disoproxil, and Others], Immune Modulator Drugs [Interferon Alpha and Pegylated Interferon], Surgery, and Vaccine), Distribution Channels (Online Pharmacies and Hospital & Retail Pharmacies)
|
|
Regional Scope
|
Asia Pacific, North America, Europe, Latin America, and Middle East & Africa
|
|
Report Coverage
|
Market scope, analysis, share, competitive analysis, growth facts, restraints, opportunities, and revenue forecast
|
|
Key Players Covered
|
Arbutus Biopharma; Dynavax Technologies; Gilead Sciences, Inc.; AbbVie Inc.; Janssen Global Services, LLC; Bristol-Myers Squibb Company; and KM Biologics
|
Hepatitis B Treatment Market Segment Insights:
Chronic segment is projected to hold significant market share
Based on types, the hepatitis B treatment market is bifurcated into chronic and acute. The chronic segment is projected to hold significant market share due to wide prevalence of acute illness of the disease. The treatment for hepatitis B involves a rigid process of diagnosis evaluating medical history and physical examination of patients. Moreover, the treatment of chronic illness includes blood tests, liver function testing, and ultrasound to prevent from severe consequences such as chronic liver disease, liver cancer, and cirrhosis.
Vaccine segment is anticipated to account for substantial share
On the basis of treatments, the market is segmented into antiviral drugs, immune modulator drugs, surgery, and vaccine. The antiviral drugs segment is further divided into entecavir, lamivudine, telbivudine, tenofovir disoproxil, and others. Furthermore, the immune modulator drugs segment is sub-categorized as interferon alpha and pegylated interferon. The vaccine segment is anticipated to account for a substantial share. The hepatitis B vaccination is made up of viral envelope proteins as well as hepatitis B surface antigens. Yeast cells are used to make the vaccine that can protect against infection as well as halt the progression of liver cancer and chronic disease caused by the illness. Growing awareness regarding the need for better healthcare services presents another key factor driving the segment growth.
Hospital & retail pharmacies segment to register a healthy growth rate
In terms of distribution channels, the hepatitis B treatment market is bifurcated into online pharmacies and hospital & retail pharmacies. The hospital & retail pharmacies segment is expected to register a healthy growth rate during the forecast period owing to the wide availability of treatment drugs and devices in hospitals and retail pharmacies. Moreover, the presence of qualified healthcare experts and reliability of prescribed medications are key factors driving the segment expansion. Furthermore, patients’ preference for hospitals visit for diagnosis due to availability of advanced facilities and specialized medical teams present another major aspects for the segment growth.
North America is expected to dominate the market
In terms of regions, the market is classified as Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America is expected to dominate the market due to the rising rate of bacterial illness, advancements in clinical techniques, and the accessibility and availability of the finest therapies for viral infection in this region. Furthermore, high healthcare expenditure and increasing number of hepatitis incidence, and mortality from hepatitis are major drivers of the regional market. Furthermore, high rates of adoption of sophisticated therapies, advantageous reimbursement policies, and the presence of well-established healthcare infrastructure are all contributing to the overall regional growth. Additionally, the presence of leading market players coupled with expanding awareness initiatives and new product launches are factors boosting the overall market expansion in the region.
Segments
Segments Covered in the Report:
By Types
By Treatments
- Antiviral Drugs
- Entecavir
- Lamivudine
- Telbivudine
- Tenofovir Disoproxil
- Others
- Immune Modulator Drugs
- Interferon Alpha
- Pegylated Interferon
- Surgery
- Vaccine
By Distribution Channels
- Online Pharmacies
- Hospital & Retail Pharmacies
By Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
By Key Players
- Arbutus Biopharma
- Dynavax Technologies
- Gilead Sciences, Inc.
- AbbVie Inc.
- Janssen Global Services, LLC
- Bristol-Myers Squibb Company
- KM Biologics
Competitive Landscape
Key players in the global hepatitis B treatment market are Arbutus Biopharma; Dynavax Technologies; Gilead Sciences, Inc.; AbbVie Inc.; Janssen Global Services, LLC; Bristol-Myers Squibb Company; and KM Biologics. These players have adopted several market development activities including collaborations, agreements, mergers & acquisitions, production capacity expansion, new product launches, and partnerships to increase their market share.
Request For Customization
Enquiry Before Buying
Speak With Analyst
